Milatuzumab, the first anti-CD74 antibody that has entered into clinical tests, is currently being studied for the treatment of non Hodgkin lymphomas, chronic lymphocytic leukemia, and multiple myeloma [33, 38] and could be potentially tested in MIF/CD74 positive CRC-pc. This evidence concerns the gene MIF and non-Hodgkin lymphoma.